1026427-11-1

Basic information

• Product Name: ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol
• Synonyms: ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol
• CAS NO: 1026427-11-1
• Molecular Weight: 231.338
• Mol File: 1026427-11-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol(1026427-11-1)
• EPA Substance Registry System: ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol(1026427-11-1)

Safety Data

• Hazardous Substances Data: 1026427-11-1(Hazardous Substances Data)

Usage

Description

((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol is a complex organic compound characterized by a unique structure that includes a benzyl group attached to a six-membered ring system with a nitrogen atom, and a hydroxyl group connected to the ring. It also features two chiral centers, allowing it to exist as a pair of enantiomers. ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol may hold potential for applications in medicinal chemistry or organic synthesis due to its intricate and potentially biologically active structure. However, further research is necessary to fully explore its properties and possible uses.

Uses

Used in Medicinal Chemistry:
((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol is used as a potential candidate in medicinal chemistry for its complex and biologically active structure, which may contribute to the development of new pharmaceuticals.
Used in Organic Synthesis:
In the field of organic synthesis, ((1R,2S,5S)-3-Benzyl-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-2-yl)-methanol serves as a valuable intermediate or building block for the creation of more complex molecules, given its unique structural features and the presence of reactive functional groups.

Upstream product

• 219753-99-8 (1S,2S,4S,7R)-6-aza-3,3-dimethyl-8-oxa-7-phenyltricyclo<4.3.0.0>nonan-5-one 
• 103201-79-2 (3R,7aS)-3-phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one 
• 134107-65-6 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 

Downstream Products

• 219754-08-2 Piv-PTL-PTL-OBn 
• 219754-03-7 (1R,2S,5S)-6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-benzyl ester 3-tert-butyl ester 
• 219754-05-9 (1R,2S,5S)-3-(2,2-Dimethyl-propionyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid benzyl ester 
• 219754-07-1 (1R,2S,5S)-6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid benzyl ester 
• 219754-02-6 (1R,2S,5S)-3-(tert-butoxycarbonyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 

Relevant articles and documents

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.